{"id":43000,"date":"2025-10-10T16:03:28","date_gmt":"2025-10-10T08:03:28","guid":{"rendered":"https:\/\/flcube.com\/?p=43000"},"modified":"2025-10-10T16:03:29","modified_gmt":"2025-10-10T08:03:29","slug":"chance-pharma-secures-exclusive-china-deal-with-huadong-medicine-for-cxg87-inhaler","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43000","title":{"rendered":"Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler"},"content":{"rendered":"\n<p>Hangzhou\u2011based Chance Pharmaceuticals Co., Ltd. has inked an exclusive commercialization agreement with Shanghai\u2011listed Huadong Medicine (<a href=\"https:\/\/www.google.com\/finance\/quote\/000963:SHE\">SHE: 000963<\/a>) for its advanced budesonide\/formoterol dry\u2011powder inhaler, <strong>CXG87<\/strong>. The deal positions CXG87 as the sole product that Chance will develop, register and supply in mainland China, while Huadong will spearhead marketing and promotion.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-deal-highlights\">Key Deal Highlights<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Exclusive Commercial Rights<\/strong> \u2013 Chance Pharma acts as the Marketing Authorization Holder (MAH), responsible for R&amp;D, registration, production and supply.<\/li>\n\n\n\n<li><strong>Financial Structure<\/strong> \u2013 Chance receives an upfront payment plus milestone\u2011linked payments tied to regulatory approval and sales targets.<\/li>\n\n\n\n<li><strong>Partner Role<\/strong> \u2013 Huadong Medicine will handle all commercialization activities, leveraging its established distribution network across China.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-product-edge\">Product Edge<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Category 2.2 Modified Drug<\/strong> \u2013 CXG87 is an independently developed formulation specifically optimized for respiratory conditions, notably asthma.<\/li>\n\n\n\n<li><strong>Superior Performance<\/strong> \u2013 Compared with AstraZeneca\u2019s Symbicort\u202fTurbuhaler, CXG87 offers more stable therapeutic efficacy and enhanced patient convenience.<\/li>\n\n\n\n<li><strong>Clinical Milestones<\/strong> \u2013 Phase\u202f3 enrollment for asthma is complete; a New Drug Application (NDA) submission is slated for the first half of 2026.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Penetration<\/strong> \u2013 The partnership gives Chance a clear entry path into China\u2019s largest respiratory\u2011disease market, while Huadong gains a differentiated inhaler to bolster its product portfolio.<\/li>\n\n\n\n<li><strong>Regulatory Advantage<\/strong> \u2013 With Chance holding the MAH status, the product can secure a streamlined regulatory pathway under China\u2019s New Drug Approval system.<\/li>\n\n\n\n<li><strong>Commercial Growth<\/strong> \u2013 The milestone payment structure aligns incentives for both parties to accelerate approval and market uptake, potentially translating into significant revenue upside.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Hangzhou\u2011based Chance Pharmaceuticals Co., Ltd. has inked an exclusive commercialization agreement with Shanghai\u2011listed Huadong Medicine&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43002,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,2623,114,887],"class_list":["post-43000","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-biotech","tag-chance-pharmaceuticals","tag-huadong-medicine","tag-she-000963"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hangzhou\u2011based Chance Pharmaceuticals Co., Ltd. has inked an exclusive commercialization agreement with Shanghai\u2011listed Huadong Medicine (SHE: 000963) for its advanced budesonide\/formoterol dry\u2011powder inhaler, CXG87. The deal positions CXG87 as the sole product that Chance will develop, register and supply in mainland China, while Huadong will spearhead marketing and promotion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43000\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler\" \/>\n<meta property=\"og:description\" content=\"Hangzhou\u2011based Chance Pharmaceuticals Co., Ltd. has inked an exclusive commercialization agreement with Shanghai\u2011listed Huadong Medicine (SHE: 000963) for its advanced budesonide\/formoterol dry\u2011powder inhaler, CXG87. The deal positions CXG87 as the sole product that Chance will develop, register and supply in mainland China, while Huadong will spearhead marketing and promotion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43000\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-10T08:03:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-10T08:03:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1002.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43000#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43000\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler\",\"datePublished\":\"2025-10-10T08:03:28+00:00\",\"dateModified\":\"2025-10-10T08:03:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43000\"},\"wordCount\":259,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43000#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1002.webp\",\"keywords\":[\"Biotech\",\"Chance Pharmaceuticals\",\"Huadong Medicine\",\"SHE: 000963\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43000#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43000\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43000\",\"name\":\"Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43000#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43000#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1002.webp\",\"datePublished\":\"2025-10-10T08:03:28+00:00\",\"dateModified\":\"2025-10-10T08:03:29+00:00\",\"description\":\"Hangzhou\u2011based Chance Pharmaceuticals Co., Ltd. has inked an exclusive commercialization agreement with Shanghai\u2011listed Huadong Medicine (SHE: 000963) for its advanced budesonide\\\/formoterol dry\u2011powder inhaler, CXG87. The deal positions CXG87 as the sole product that Chance will develop, register and supply in mainland China, while Huadong will spearhead marketing and promotion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43000#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43000\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43000#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1002.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1002.webp\",\"width\":1080,\"height\":608,\"caption\":\"Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43000#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler - Insight, China&#039;s Pharmaceutical Industry","description":"Hangzhou\u2011based Chance Pharmaceuticals Co., Ltd. has inked an exclusive commercialization agreement with Shanghai\u2011listed Huadong Medicine (SHE: 000963) for its advanced budesonide\/formoterol dry\u2011powder inhaler, CXG87. The deal positions CXG87 as the sole product that Chance will develop, register and supply in mainland China, while Huadong will spearhead marketing and promotion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43000","og_locale":"en_US","og_type":"article","og_title":"Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler","og_description":"Hangzhou\u2011based Chance Pharmaceuticals Co., Ltd. has inked an exclusive commercialization agreement with Shanghai\u2011listed Huadong Medicine (SHE: 000963) for its advanced budesonide\/formoterol dry\u2011powder inhaler, CXG87. The deal positions CXG87 as the sole product that Chance will develop, register and supply in mainland China, while Huadong will spearhead marketing and promotion.","og_url":"https:\/\/flcube.com\/?p=43000","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-10T08:03:28+00:00","article_modified_time":"2025-10-10T08:03:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1002.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43000#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43000"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler","datePublished":"2025-10-10T08:03:28+00:00","dateModified":"2025-10-10T08:03:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43000"},"wordCount":259,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43000#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1002.webp","keywords":["Biotech","Chance Pharmaceuticals","Huadong Medicine","SHE: 000963"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43000#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43000","url":"https:\/\/flcube.com\/?p=43000","name":"Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43000#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43000#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1002.webp","datePublished":"2025-10-10T08:03:28+00:00","dateModified":"2025-10-10T08:03:29+00:00","description":"Hangzhou\u2011based Chance Pharmaceuticals Co., Ltd. has inked an exclusive commercialization agreement with Shanghai\u2011listed Huadong Medicine (SHE: 000963) for its advanced budesonide\/formoterol dry\u2011powder inhaler, CXG87. The deal positions CXG87 as the sole product that Chance will develop, register and supply in mainland China, while Huadong will spearhead marketing and promotion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43000#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43000"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43000#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1002.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1002.webp","width":1080,"height":608,"caption":"Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43000#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1002.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43000"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43000\/revisions"}],"predecessor-version":[{"id":43003,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43000\/revisions\/43003"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43002"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}